<p>剑桥投资研究顾问公司在最近向美国证券交易委员会提交的 13F 表格中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）的持股增加了 13.6%。该公司在本季度购买了 39,573 股后，持有该医疗产品制造商的 331,204 股股票。根据其最近向美国证券交易委员会的提交，剑桥投资研究顾问公司在雅培的持股价值为 41,497,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>艾伯维发出健康趋势跟随信号：反弹即将到来？</li>
</ul>
<p>其他机构投资者最近也买入和卖出了该公司的股票。WealthPlan Investment Management LLC 在第四季度将其在雅培的持股增加了 258.7%。WealthPlan Investment Management LLC 现在拥有 23,713 股该医疗产品制造商的股票，价值为 2,971,000 美元，此前在上个季度又购买了 17,102 股。Noesis Capital Management Corp 在第四季度将其在雅培的持股增加了 9.9%。Noesis Capital Management Corp 现在拥有 1,966 股该医疗产品制造商的股票，价值为 246,000 美元，此前在此期间又购买了 177 股。Lawood &amp; Co.在第四季度购买了雅培的新头寸，价值为 332,000 美元。Novare Capital Management LLC 在第四季度将其在雅培的持股增加了 1.3%。Novare Capital Management LLC 现在拥有 104,349 股该医疗产品制造商的股票，价值为 13,074,000 美元，此前在此期间又购买了 1,294 股。最后，Cauble &amp; Harre Wealth Management Inc.在第四季度购买了雅培的新头寸，价值为 404,000 美元。目前 75.18% 的股票由机构投资者和对冲基金持有。</p>
<h2>内部买卖</h2>
<p>在其他消息中，董事 Daniel J. Starks 在 4 月 27 日星期一购买了 10,000 股公司的股票。每股购买价格为 92.65 美元，总价值为 926,500.00 美元。交易完成后，该董事直接持有公司 6,751,103 股股票，价值为 625,489,692.95 美元。这笔交易代表其持股增加了 0.15%。该购买在向证券交易委员会的提交中披露，可以通过此链接访问。此外，高级副总裁 Eric Shroff 在 3 月 2 日星期一出售了 709 股雅培的股票。每股出售价格为 115.58 美元，总交易额为 81,946.22 美元。交易完成后，该高级副总裁直接持有公司 39,164 股股票，价值约为 4,526,575.12 美元。这代表其持股减少了 1.78%。该出售的披露在 SEC 提交中可用。在过去 90 天内，内部人士已出售 3,055 股公司股票，价值为 353,097 美元。0.46% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>雅培股票崩盘：反弹可能即将到来</li>
</ul>
<p>一些研究分析师对该股票发表了评论。Oppenheimer 在 4 月 17 日的研究报告中将雅培的目标价从 132.00 美元下调至 115.00 美元，并对该股票给予 “跑赢大盘” 的评级。Sanford C. Bernstein 在 4 月 17 日的研究报告中将雅培的目标价从 125.00 美元下调至 110.00 美元，并对该公司给予 “跑赢大盘” 的评级。巴克莱在 4 月 20 日的研究报告中将雅培的目标价从 144.00 美元下调至 143.00 美元，并对该公司给予 “增持” 的评级。美国银行在 4 月 17 日的报告中将雅培的目标价从 150.00 美元下调至 120.00 美元，并对该公司给予 “买入” 的评级。最后，Leerink Partners 在 4 月 21 日的报告中将雅培的目标价从 119.00 美元下调至 106.00 美元，并对该公司给予 “市场表现” 的评级。两位研究分析师对该股票给予强烈买入评级，十九位给予买入评级，五位给予持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 119.43 美元。</p>
<p><strong>获取我们最新的 ABT 研究报告</strong></p>
<h2>雅培股票表现</h2>
<ul>
<li>一家股息之王正在打折出售：雅培实验室是医疗保健的便宜货吗？</li>
</ul>
<p>雅培的股票在周一开盘价为 84.49 美元。雅培的年低为 81.97 美元，年高为 139.06 美元。该公司的 50 日移动平均线为 99.02 美元，200 日移动平均线为 113.25 美元。该股票的市值为 1471.6 亿美元，市盈率为 23.67，PEG 比率为 1.41，贝塔值为 0.65。该公司的债务与股本比率为 0.56，流动比率为 1.39，速动比率为 1.01。</p>
<p>雅培（NYSE:ABT - 获取免费报告）最近在 4 月 16 日星期四发布了季度财报。该医疗产品制造商报告本季度每股收益（EPS）为 1.15 美元，超出分析师一致预期的 1.14 美元，超出 0.01 美元。该业务在本季度的收入为 111.6 亿美元，而分析师预期为 109.9 亿美元。雅培的净利润率为 13.90%，股本回报率为 17.62%。该公司的收入较去年同期增长了 7.8%。在去年同期，该公司每股收益为 1.09 美元。雅培已将其 2026 财年的指引设定为每股收益 5.380-5.580 美元，2026 年第二季度的指引设定为每股收益 1.250-1.310 美元。平均而言，股票研究分析师预计雅培在当前年度的每股收益将达到 5.48 美元。</p>
<h2>雅培宣布分红</h2>
<p>该公司最近宣布了季度股息，并于 5 月 15 日（星期五）支付。4 月 15 日（星期三）登记在册的股东获得了每股 0.63 美元的股息。该股息的除息日为 4 月 15 日（星期三）。这相当于每年 2.52 美元的股息，股息收益率为 3.0%。雅培的股息支付比率（DPR）目前为 70.59%。</p>
<h2>关于雅培</h2>
<p>（免费报告）</p>
<p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、生产和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断领域，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性疾病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过雅培</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>当博通市值超过 2 万亿美元时，私人信贷巨头想要参与</li>
<li>通过这些 ETF 瞄准火热的分拆和合并领域</li>
<li>随着人工智能内存需求激增，三星加入 1 万亿美元俱乐部</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

美国制药 ETF - iShares

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

基因改革 ETF - ARK

医疗业 ETF - Vanguard

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

<p>剑桥投资研究顾问公司（Cambridge Investment Research Advisors Inc.）在第四季度将其在雅培（Abbott Laboratories，NYSE:ABT）的持股增加了 13.6%，目前持有 331,204 股，价值 4150 万美元。其他投资者也提高了他们的持股比例。内部交易方面，董事丹尼尔·J·斯塔克斯（Daniel J. Starks）购买了 10,000 股，高级副总裁埃里克·肖夫（Eric Shroff）出售了 709 股。分析师已调整了雅培的目标价格，平均目标为 119.43 美元，并给予 “适度买入” 的评级</p>

<p>Cambridge Investment Research Advisors Inc. raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 13.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 331,204 shares of the healthcare product maker's stock after purchasing an additional 39,573 shares during the quarter. Cambridge Investment Research Advisors Inc.'s holdings in Abbott Laboratories were worth $41,497,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>剑桥投资研究顾问公司在最近向美国证券交易委员会提交的 13F 表格中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）的持股增加了 13.6%。该公司在本季度购买了 39,573 股后，持有该医疗产品制造商的 331,204 股股票。根据其最近向美国证券交易委员会的提交，剑桥投资研究顾问公司在雅培的持股价值为 41,497,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维发出健康趋势跟随信号：反弹即将到来？</li>
</ul>
</div><p>Other institutional investors also recently bought and sold shares of the company. WealthPlan Investment Management LLC raised its position in shares of Abbott Laboratories by 258.7% in the fourth quarter. WealthPlan Investment Management LLC now owns 23,713 shares of the healthcare product maker's stock valued at $2,971,000 after buying an additional 17,102 shares during the last quarter. Noesis Capital Mangement Corp boosted its stake in shares of Abbott Laboratories by 9.9% in the fourth quarter. Noesis Capital Mangement Corp now owns 1,966 shares of the healthcare product maker's stock valued at $246,000 after purchasing an additional 177 shares during the period. Lawood &amp; Co. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $332,000. Novare Capital Management LLC boosted its stake in shares of Abbott Laboratories by 1.3% in the fourth quarter. Novare Capital Management LLC now owns 104,349 shares of the healthcare product maker's stock valued at $13,074,000 after purchasing an additional 1,294 shares during the period. Finally, Cauble &amp; Harre Wealth Management Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at $404,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者最近也买入和卖出了该公司的股票。WealthPlan Investment Management LLC 在第四季度将其在雅培的持股增加了 258.7%。WealthPlan Investment Management LLC 现在拥有 23,713 股该医疗产品制造商的股票，价值为 2,971,000 美元，此前在上个季度又购买了 17,102 股。Noesis Capital Management Corp 在第四季度将其在雅培的持股增加了 9.9%。Noesis Capital Management Corp 现在拥有 1,966 股该医疗产品制造商的股票，价值为 246,000 美元，此前在此期间又购买了 177 股。Lawood &amp; Co.在第四季度购买了雅培的新头寸，价值为 332,000 美元。Novare Capital Management LLC 在第四季度将其在雅培的持股增加了 1.3%。Novare Capital Management LLC 现在拥有 104,349 股该医疗产品制造商的股票，价值为 13,074,000 美元，此前在此期间又购买了 1,294 股。最后，Cauble &amp; Harre Wealth Management Inc.在第四季度购买了雅培的新头寸，价值为 404,000 美元。目前 75.18% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, Director Daniel J. Starks purchased 10,000 shares of the company's stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Daniel J. Starks 在 4 月 27 日星期一购买了 10,000 股公司的股票。每股购买价格为 92.65 美元，总价值为 926,500.00 美元。交易完成后，该董事直接持有公司 6,751,103 股股票，价值为 625,489,692.95 美元。这笔交易代表其持股增加了 0.15%。该购买在向证券交易委员会的提交中披露，可以通过此链接访问。此外，高级副总裁 Eric Shroff 在 3 月 2 日星期一出售了 709 股雅培的股票。每股出售价格为 115.58 美元，总交易额为 81,946.22 美元。交易完成后，该高级副总裁直接持有公司 39,164 股股票，价值约为 4,526,575.12 美元。这代表其持股减少了 1.78%。该出售的披露在 SEC 提交中可用。在过去 90 天内，内部人士已出售 3,055 股公司股票，价值为 353,097 美元。0.46% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Abbott Stock Crash: Rebound Could Be Coming Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培股票崩盘：反弹可能即将到来</li>
</ul>
</div><p>A number of research analysts have commented on the stock. Oppenheimer reduced their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday, April 17th. Sanford C. Bernstein decreased their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an &#34;outperform&#34; rating for the company in a research report on Friday, April 17th. Barclays reduced their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, April 20th. Bank of America decreased their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a &#34;buy&#34; rating for the company in a report on Friday, April 17th. Finally, Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a &#34;market perform&#34; rating for the company in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $119.43.</p>
<div class="lb-trans"><p>一些研究分析师对该股票发表了评论。Oppenheimer 在 4 月 17 日的研究报告中将雅培的目标价从 132.00 美元下调至 115.00 美元，并对该股票给予 “跑赢大盘” 的评级。Sanford C. Bernstein 在 4 月 17 日的研究报告中将雅培的目标价从 125.00 美元下调至 110.00 美元，并对该公司给予 “跑赢大盘” 的评级。巴克莱在 4 月 20 日的研究报告中将雅培的目标价从 144.00 美元下调至 143.00 美元，并对该公司给予 “增持” 的评级。美国银行在 4 月 17 日的报告中将雅培的目标价从 150.00 美元下调至 120.00 美元，并对该公司给予 “买入” 的评级。最后，Leerink Partners 在 4 月 21 日的报告中将雅培的目标价从 119.00 美元下调至 106.00 美元，并对该公司给予 “市场表现” 的评级。两位研究分析师对该股票给予强烈买入评级，十九位给予买入评级，五位给予持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 119.43 美元。</p>
</div><p><strong>Get Our Latest Research Report on ABT</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 ABT 研究报告</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><ul>
<li>A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?</li>
</ul>
<div class="lb-trans"><ul>
<li>一家股息之王正在打折出售：雅培实验室是医疗保健的便宜货吗？</li>
</ul>
</div><p>Shares of ABT opened at $84.49 on Monday. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a 50-day moving average of $99.02 and a two-hundred day moving average of $113.25. The stock has a market cap of $147.16 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 1.41 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.</p>
<div class="lb-trans"><p>雅培的股票在周一开盘价为 84.49 美元。雅培的年低为 81.97 美元，年高为 139.06 美元。该公司的 50 日移动平均线为 99.02 美元，200 日移动平均线为 113.25 美元。该股票的市值为 1471.6 亿美元，市盈率为 23.67，PEG 比率为 1.41，贝塔值为 0.65。该公司的债务与股本比率为 0.56，流动比率为 1.39，速动比率为 1.01。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm's revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近在 4 月 16 日星期四发布了季度财报。该医疗产品制造商报告本季度每股收益（EPS）为 1.15 美元，超出分析师一致预期的 1.14 美元，超出 0.01 美元。该业务在本季度的收入为 111.6 亿美元，而分析师预期为 109.9 亿美元。雅培的净利润率为 13.90%，股本回报率为 17.62%。该公司的收入较去年同期增长了 7.8%。在去年同期，该公司每股收益为 1.09 美元。雅培已将其 2026 财年的指引设定为每股收益 5.380-5.580 美元，2026 年第二季度的指引设定为每股收益 1.250-1.310 美元。平均而言，股票研究分析师预计雅培在当前年度的每股收益将达到 5.48 美元。</p>
</div><h2>Abbott Laboratories Announces Dividend</h2>
<div class="lb-trans"><h2>雅培宣布分红</h2>
</div><p>The company also recently declared a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. Abbott Laboratories's dividend payout ratio (DPR) is currently 70.59%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，并于 5 月 15 日（星期五）支付。4 月 15 日（星期三）登记在册的股东获得了每股 0.63 美元的股息。该股息的除息日为 4 月 15 日（星期三）。这相当于每年 2.52 美元的股息，股息收益率为 3.0%。雅培的股息支付比率（DPR）目前为 70.59%。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>关于雅培</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、生产和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断领域，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性疾病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li>
<li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li>
<li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li>
<li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过雅培</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>当博通市值超过 2 万亿美元时，私人信贷巨头想要参与</li>
<li>通过这些 ETF 瞄准火热的分拆和合并领域</li>
<li>随着人工智能内存需求激增，三星加入 1 万亿美元俱乐部</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc.

Market Beat

艾伯维

奥本海默控股

巴克莱银行

美国银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

剑桥投资研究顾问公司购买了雅培公司 $ABT 的股票